Plasma steroid concentrations reflect acute disease severity and normalise during recovery in people hospitalised with COVID-19.
Devine K., Russell CD., Blanco GR., Walker BR., Homer NZM., Denham SG., Simpson JP., Leavy OC., Elneima O., McAuley HJC., Shikotra A., Singapuri A., Sereno M., Saunders RM., Harris VC., Houchen-Wolloff L., Greening NJ., Lone NI., Thorpe M., Greenhalf W., Chalmers JD., Ho L-P., Horsley A., Marks M., Raman B., Moore SC., Dunning J., Semple MG., Andrew R., Wain LV., Evans RA., Brightling CE., Kenneth Baillie J., Reynolds RM., ISARIC4C Investigators and PHOSP-COVID Study Collaborative Group None.
OBJECTIVE: Endocrine systems are disrupted in acute illness, and symptoms reported following coronavirus disease 2019 (COVID-19) are similar to those found with clinical hormone deficiencies. We hypothesised that people with severe acute COVID-19 and with post-COVID symptoms have glucocorticoid and sex hormone deficiencies. DESIGN/PATIENTS: Samples were obtained for analysis from two UK multicentre cohorts during hospitalisation with COVID-19 (International Severe Acute Respiratory Infection Consortium/World Health Organisation [WHO] Clinical Characterization Protocol for Severe Emerging Infections in the UK study), and at follow-up 5 months after hospitalisation (Post-hospitalisation COVID-19 study). MEASUREMENTS: Plasma steroids were quantified by liquid chromatography-mass spectrometry. Steroid concentrations were compared against disease severity (WHO ordinal scale) and validated symptom scores. Data are presented as geometric mean (SD). RESULTS: In the acute cohort (n = 239, 66.5% male), plasma cortisol concentration increased with disease severity (cortisol 753.3 [1.6] vs. 429.2 [1.7] nmol/L in fatal vs. least severe, p